eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2023
vol. 48
 
Share:
Share:
abstract:
Experimental immunology

Novel inflammatory markers in patients with severe COVID-19 and a pulmonary thrombotic event

Jarosław Bakiera
1
,
Karolina Strzelec-Pawełczak
2
,
Katarzyna Czarnek
3
,
Ida Osuchowska-Grochowska
2
,
Jacek Bogucki
4
,
Agnieszka Markiewicz-Gospodarek
2
,
Aleksandra Górska
2
,
Zuzanna Chilimoniuk
2
,
Sebastian Radej
2, 3
,
Mateusz Szymański
2
,
Piero Portincasa
5
,
Cezary Grochowski
2, 3

  1. Department of Laboratory Diagnostics, Coagulation and Microbiology, Stefan Wyszyński Regional Specialist Hospital, Lublin, Poland
  2. Department of Human Anatomy, Medical University of Lublin, Lublin
  3. Institute of Health Sciences, The John Paul II Catholic University of Lublin, Lublin, Poland
  4. Department of Organic Chemistry, Medical University of Lublin, Lublin, Poland
  5. Clinica Medica “A. Murri”, Department of Biomedical Sciences & Human Oncology, University of Bari “Aldo Moro” Medical School, Bari, Italy
Cent Eur J Immunol 2023; 48 (3): 167-173
Online publish date: 2023/09/21
View full text Get citation
 
PlumX metrics:
Venous thromboembolism (VTE), clinically manifested as deep vein thrombosis (DVT) or acute pulmonary embolism (PE), is the third most common acute cardiovascular syndrome following myocardial infarction and stroke. The annual incidence of PE is between 39 and 115 per 100,000 inhabitants. The incidence of VTE is almost eight times higher in people aged 80 and older than in the fifth decade of life. We performed a retrospective study of 226 COVID-19 patients and selected group of patients who experienced a pulmonary thrombotic event. The incidence of PE in hospitalized COVID-19 patients was approximately 1.9-8.9%. The retrospective nature of the analyzed cohorts and relatively short observation periods could have led to underestimation of the actual incidence of PE. This study underlines the role of novel inflammatory biomarkers such as neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with a pulmonary thrombotic event in COVID-19. We suggest that these biomarkers may have high assessment value and complement routinely used biomarkers.
keywords:

pulmonary embolism, COVID-19, novel inflammatory markers

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.